ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 376-380

  Boleti, Ekaterini ^a   Mead, G M ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

ABVD; Chemotherapy; GCSF; Growth factors; Hodgkin lymphoma; Neutropenia

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GROWTH FACTOR; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL COUNT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HODGKIN DISEASE; HUMAN; INFECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GRANULOCYTES; HODGKIN DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 33847270617     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl397     Document Type: Article

References (30)

1. Bonadonna G, De Lena M, Monfardini S et al. Combination usage of Adriamycin (NSC-123127). Cancer Chemother Rep 1975; 6: 381-388.
2. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
3. Viviani S, Ragni G, Santoro A et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389-1392.
4. De Vita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881-895.
5. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
6. Duggan DB, Petroni GR. Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
7. Straus DJ, Portlock GS, Qin J et al. Results of a prospective randomized clinical trail of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease. Blood 2004; 73: 3483-3489.
8. Gustavsson A. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Acta Oncol 1997; 36: 483-488.
9. Carde P, Mackintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146-153.
10. van Rijswijk RE, Haanen C, Dekker AW et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776-1782.
11. Landgren O, Algernon C, Axdorph U et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88: 438-444.
12. Smith TJ. Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guidelines. J Clin Oncol 2006; 19: 3187-3205.
13. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
14. Santoro A, Bonadonna G, Valagussa P et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
15. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
16. Rueda A, Sevilla I, Guma J et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001; 41: 353-358.
17. Silvestri F, Fanin R, Velisig M et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumori 1994; 80: 453-458.
18. Johnson PWM, Radford JA, Cullen MH et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208-9218.
19. Martin WG, Ristow KM, Habermann TM et al. Bleomycin pulmonary toxicity has a negative impact on the outcome at patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614-7620.
20. Aapro MS, Cameron DA. Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
21. ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol 2005; 16 (Suppl 1): I80-i82.
22. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Cancer Netw 2005; 3: 557-571.
23. Chand VK, Link BK, Ritchie JM et al. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma 2006; 47: 657-663.
24. Clarke K, Grigg A. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease. Leuk Lymphoma 1995; 19: 521-522.
25. Hirsch A, Vander Els N, Straus DJ et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14: 1297-1305.
26. Martin WG, Habermann TM, Colgan JP et al. G-CSF Administration increases pulmonary toxicity for Hodgkin's disease patients treated with bleomycin-containing chemotherapy. Blood 2004 (ASH Annual Meeting Abstracts); 104: (Abstr 1317).
27. Saxman SB, Nichols CR, Einhom LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997; 111: 657-660.
28. Adams JR. When the risk of febrile neutropenia is 20% prophylactic colony-stimulating factor use is clinically effective but is it cost-effective? J Clin Oncol 2006; 24: 2975-2977.
29. Hartmann LC, Tschetter LK, Habermann TM et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997; 336: 1776-1780.
30. Jones SE, Schottstaedt MW, Duncan LA et al. Randomized double-blind prospective trial to evaluate the effects of sagramostin versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 1996; 14: 2976-2983.